Screener
BioCryst Pharmaceuticals BCRX Non-cash Interest expense on Royalty financing obligations
Non-cash Interest expense on Royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Balance as of December 31, 2025 | $ | $169,559 | $ | $172,671 | $ | $123,458 | $ | $465,688 |
| Non-cash interest expense on royalty financing obligations | 10,111 | — | 3,183 | 13,294 | ||||
| Royalty revenues payable | (14,132) | (1,220) | (16,132) | (31,484) | ||||
| Balance as of March 31, 2026 | $ | $165,538 | $ | $171,451 | $ | $110,509 | $ | $447,498 |
| Non-cash interest expense on royalty financing obligations | 10,159 | — | 2,877 | 13,036 | ||||
| Royalty revenues paid and payable | (15,148) | (1,309) | (17,288) | (33,745) | ||||
| Balance as of June 30, 2026 | $ | $160,549 | $ | $170,142 | $ | $96,098 | $ | $426,789 |
| Effective interest rate | 24.0 | — | 10.3 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported non-cash interest expense on royalty financing obligations of $13.04M in Q2 2026.
- How has BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations decreased by 2.7% year-over-year, from $13.4M to $13.04M.
- What is the long-term trend for BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations has grown at a -11.4% compound annual growth rate (CAGR), from $76.48M to $53.16M.
- What does non-cash interest expense on royalty financing obligations mean?
- Non-cash Interest expense on Royalty financing obligations as reported by BioCryst Pharmaceuticals Inc.
Ask your AI about BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude